Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: @milestone

Sorry, I don't get, what you are trying to say without saying it... - of course I read the footnotes AND the headline, which says:

"Ownership of Shares of Common Stock as of August 2002".

(LV owns 27mio)

And the footnote says:

"This number includes 10,189,662 shares of common stock issuable upon exercise of outstanding warrants previously issued to Lincoln which are currently exercisable, which shares would not be deemed beneficially owned..."

Read the "KEY FACTS" and it says, LV had 27mio PRIOR the offer and 10mio AFTER the offer, still 10.27% of PTSC - IF LV converts the warrants.

But I'm referring to the PRIOR date to show, that LV had more than 4.99% or 9.99%, so, please, tell me, where my mistake lies (I don't have a problem to accept one), but don't make a lesson out of it.

Once again: TIA

Share
New Message
Please login to post a reply